- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
Daratumumab Significantly Extended Progression-Free Survival in Combination with Lenalidomide and Dexamethasone in Patients with Multiple Myeloma
- Data from Phase 3 MMY3003 (POLLUX) trial to be featured in the Presidential Symposium at the European Hematology Association (EHA) Annual Congress (Abstract LB2238) - Phase 3 MMY3004 (CASTOR) trial data will also be highlighted at EHA - Together, these results show the potential of daratumumab in combination with either a proteasome inhibitor or immunomodulatory agent
New Janssen Phase 3 Data in Patients with Moderately to Severely Active Rheumatoid Arthritis Shows Sirukumab Significantly Inhibited Radiographic Progression and Improved Signs and Symptoms of Disease
Sirukumab One-year Radiographic Data Show Significant Inhibition of Joint Destruction
Yoshinori Ohsumi, Ph.D., Wins 2016 Dr. Paul Janssen Award for Biomedical Research
As part of an ongoing commitment to support life sciences innovators and the development of integrated, cross-sector solutions to prevent, intercept and cure diseases, Johnson & Johnson today named cell biologist Yoshinori Ohsumi, Ph.D., of the Tokyo Institute of Technology the winner of the 2016 Dr. Paul Janssen Award for Biomedical Research for his pioneering discoveries concerning the molecular basis of autophagy.
Janssen Expands Body of Evidence for INVOKANA® (canagliflozin) with 18 New Data Presentations at American Diabetes Association’s 76th Scientific Sessions®
Comparative Analyses with DPP-4 Inhibitors, Including Sitagliptin, and Findings on Use in Weight Management and Type 1 Diabetes Underscore Janssen Commitment to Improving Diabetes Management
New Idylla™ Ebola Virus Triage Test Granted Emergency Use Authorization by U.S. FDA
Co-Developed by Janssen Diagnostics, test will help prevent future outbreaks of Ebola
SIMPONI® Receives CHMP Positive Opinion For Treatment Of Polyarticular Juvenile Idiopathic Arthritis
SIMPONI Recommended for Sixth Indication in Europe and First in Pediatric Population
U.S. FDA Expands Indication of INVOKAMET® (canagliflozin/metformin HCl) to Include First-Line Treatment of Adults with Type 2 Diabetes
In a Phase 3 study of patients not previously treated with any diabetes medication, combination therapy with canagliflozin and metformin lowered blood sugar more than either medicine alone
New Phase 3 Study Findings Show STELARA® Maintained Clinical Remission After One Year Of Treatment In Patients With Moderate To Severe Crohn’s Disease
Approximately 50 Percent of STELARA®-treated Patients Achieved Clinical Remission According to Pivotal Phase 3 IM-UNITI Study Results Presented for the First Time at Digestive Disease Week® 2016